HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 03-23-2013, 09:49 AM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatme

http://clinicaltrials.gov/show/NCT01220128

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Phase I segment of the study: occurrence of severe toxicities. [ Time Frame: On a continuous basis during the whole study duration (Day 0 to 36 months after concluding visit-30 days post-surgery). ] [ Designated as safety issue: No ]
  • Phase I segment of the study: immunogenicity to constituent of the investigational immunotherapy. [ Time Frame: Post study treatment Dose 4, evaluated using a blood sample collected at Visit 5, after 13 weeks of treatment. ] [ Designated as safety issue: No ]
  • Phase II segment of the study: occurrence of severe toxicities. [ Time Frame: On a continuous basis during the whole study duration (Day 0 to 36 months after concluding visit). ] [ Designated as safety issue: No ]
  • Phase II segment of the study: occurrence of adverse events and serious adverse events. [ Time Frame: On a continuous basis during the study treatment period and ending 30 days after the last study treatment administration (Week 16 or 22 depending on the chemotherapy regimen). ] [ Designated as safety issue: No ]
  • Phase II segment of the study: occurrence of serious adverse events related to study treatment. [ Time Frame: On a continuous basis during the whole study duration (Day 0 to 36 months after concluding visit). ] [ Designated as safety issue: No ]
  • Phase II segment of the study: Immunogenicity to constituent of the investigational immunotherapy. [ Time Frame: At treatment start, after 10, 13 and 16 weeks of treatment, or after 10, 13, 19 and 22 weeks of treatment depending on the treatment regimen, at concluding Visit, as well as after 6 and 12 months after concluding visit. ] [ Designated as safety issue: No ]
  • Phase II segment of the study: clinical activity (The pathological response in the breast and axillary nodes at the definitive surgery). [ Time Frame: At surgery (pathological complete response). ] [ Designated as safety issue: No ]
  • Phase II segment of the study: other indicators of clinical activity (Disease free survival and Overall survival). [ Time Frame: From surgery onwards until the end of the post study contact (6 years after the concluding visit). ] [ Designated as safety issue: No ]


Estimated Enrollment: 180 Study Start Date: April 2011 Estimated Study Completion Date: October 2018 Estimated Primary Completion Date: March 2016 (Final data collection date for primary outcome measure)
__________________
Diagnosed 2007
Stage IIb Invasive Ductal Carcinoma, Pagets, 3 of 15 positive nodes

Traditional Treatment: Mastectomy and Axillary Node Dissection followed by Taxotere, 6 treatments and 1 year of Herceptin, no radiation
Former Chemo Ninja "Takizi Zukuchiri"

Additional treatments:
GP2 vaccine, San Antonio Med Ctr
Prescriptive Exercise for Cancer Patients
ENERGY Study, UCSD La Jolla

Reconstruction: TRAM flap, partial loss, Revision

The content of my posts are meant for informational purposes only. The medical information is intended for general information only and should not be used in any way to diagnose, treat, cure, or prevent disease
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 01:55 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2018, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter